In Phase C, individuals will get ABBV-744 and oral navitoclax. In Phase D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will acquire treatment until disorder progression or maybe the contributors are unable to tolerate the study drugs. For all circulation cytometry experiments, ten,000 cells for each replicate were being analyzed, https://jackg544seo6.national-wiki.com/user